company background image
301211 logo

Hubei Biocause Heilen Pharmaceutical SZSE:301211 Stock Report

Last Price

CN¥19.18

Market Cap

CN¥5.5b

7D

-8.6%

1Y

-28.3%

Updated

22 Nov, 2024

Data

Company Financials

Hubei Biocause Heilen Pharmaceutical Co., Ltd.

SZSE:301211 Stock Report

Market Cap: CN¥5.5b

Hubei Biocause Heilen Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hubei Biocause Heilen Pharmaceutical
Historical stock prices
Current Share PriceCN¥19.18
52 Week HighCN¥26.98
52 Week LowCN¥13.63
Beta0.98
11 Month Change13.22%
3 Month Change35.45%
1 Year Change-28.27%
33 Year Changen/a
5 Year Changen/a
Change since IPO-38.33%

Recent News & Updates

Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Shareholders Have More To Worry About Than Lackluster Earnings

Nov 04
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Shareholders Have More To Worry About Than Lackluster Earnings

Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211) After Shares Rise 43%

Oct 30
Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211) After Shares Rise 43%

Recent updates

Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Shareholders Have More To Worry About Than Lackluster Earnings

Nov 04
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Shareholders Have More To Worry About Than Lackluster Earnings

Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211) After Shares Rise 43%

Oct 30
Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211) After Shares Rise 43%

Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211)

Aug 07
Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211)

Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Will Pay A Larger Dividend Than Last Year At CN¥0.48

May 22
Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Will Pay A Larger Dividend Than Last Year At CN¥0.48

Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations

Apr 29
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations

Shareholder Returns

301211CN PharmaceuticalsCN Market
7D-8.6%-1.5%-2.1%
1Y-28.3%-9.4%2.8%

Return vs Industry: 301211 underperformed the CN Pharmaceuticals industry which returned -4.8% over the past year.

Return vs Market: 301211 underperformed the CN Market which returned 5.4% over the past year.

Price Volatility

Is 301211's price volatile compared to industry and market?
301211 volatility
301211 Average Weekly Movement10.5%
Pharmaceuticals Industry Average Movement7.3%
Market Average Movement8.3%
10% most volatile stocks in CN Market12.6%
10% least volatile stocks in CN Market5.6%

Stable Share Price: 301211's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 301211's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
19951,012Qun Liangwww.biocause.com

Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company provides APIs and intermediates, and formulations; and dimethyl ether gas and a-chloropropionyl chloride chemical products.

Hubei Biocause Heilen Pharmaceutical Co., Ltd. Fundamentals Summary

How do Hubei Biocause Heilen Pharmaceutical's earnings and revenue compare to its market cap?
301211 fundamental statistics
Market capCN¥5.52b
Earnings (TTM)CN¥106.26m
Revenue (TTM)CN¥454.57m

52.0x

P/E Ratio

12.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
301211 income statement (TTM)
RevenueCN¥454.57m
Cost of RevenueCN¥309.16m
Gross ProfitCN¥145.41m
Other ExpensesCN¥39.15m
EarningsCN¥106.26m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.37
Gross Margin31.99%
Net Profit Margin23.38%
Debt/Equity Ratio0%

How did 301211 perform over the long term?

See historical performance and comparison

Dividends

2.5%

Current Dividend Yield

130%

Payout Ratio